When Cardiac Amyloidosis vs Hypertensive Heart Disease Should Be Considered in Older Adults with Unexplained LVH

If you or a loved one is 77 or older and has been found to have left ventricular hypertrophy (LVH)—a thickening of the heart’s main pumping chamber—yet your blood pressure is well-controlled or only mildly elevated, it’s natural to wonder: Is this just from years of high BP, or could something else be going on? That’s where understanding the difference between cardiac amyloidosis vs hypertensive heart disease becomes especially important. For adults over 50, this distinction isn’t just academic—it guides treatment, prognosis, and peace of mind. A common misconception is that LVH in older age must be due to long-standing hypertension. Another is that “normal troponin” rules out serious heart muscle disease—yet in early cardiac amyloidosis, troponin often remains within standard lab ranges even as subtle damage accumulates.

What makes this especially relevant today is how frequently obesity coexists with aging—and how that changes what we see on tests like the ECG. In people with higher BMI, the heart may develop diastolic stiffness (difficulty relaxing between beats) not from pressure overload alone, but from infiltration or metabolic strain—and the classic ECG voltage signs of LVH can become misleading. So let’s walk through when to gently pause and consider other possibilities—and how modern tools help bring clarity.

Why Cardiac Amyloidosis vs Hypertensive Heart Disease Matters in High-BMI Older Adults

The heart remodels in response to stress—but how it remodels tells us a great deal about why. In hypertensive heart disease, chronic arterial pressure causes the heart muscle to thicken symmetrically, usually over decades. In cardiac amyloidosis, abnormal proteins (most often transthyretin or light-chain amyloid) deposit within the heart tissue itself, leading to stiff, heavy, and sometimes slightly enlarged walls—even without high BP. This is why up to 15% of adults over 75 with unexplained LVH and preserved ejection fraction are later diagnosed with cardiac amyloidosis, particularly the wild-type transthyretin (ATTRwt) form.

Here’s what makes the distinction so clinically meaningful:

• Treatment paths differ greatly. Blood pressure control remains essential in hypertensive heart disease—but in cardiac amyloidosis, certain BP-lowering drugs (like ACE inhibitors or ARBs) may need cautious use, while others (like tafamidis for ATTR) offer disease-modifying benefits.
• Prognosis varies: Untreated cardiac amyloidosis carries a median survival of ~3–5 years from diagnosis, whereas well-managed hypertensive heart disease often supports stable function for many more years.
• Obesity adds nuance: In individuals with BMI ≥30 kg/m², echocardiographic measurements can underestimate true wall thickness due to acoustic shadowing, while ECG voltage criteria (e.g., Sokolow-Lyon or Cornell voltage) become less reliable—up to 40% of obese older adults with confirmed LVH on echo will have normal ECG voltage. So relying solely on ECG can delay recognition of infiltrative disease.

How to Assess Beyond the Basics: Strain, Biomarkers, and Imaging Clues

When LVH appears out of proportion to measured BP—or when symptoms like fatigue, shortness of breath with minimal activity, or unexplained weight loss emerge—the diagnostic lens should widen. Here’s what modern evaluation looks like:

• Echocardiographic strain imaging is now a cornerstone. In hypertensive heart disease, global longitudinal strain (GLS) is typically mildly reduced (e.g., –18% to –20%), but relatively uniform. In cardiac amyloidosis, GLS is characteristically severely reduced (often ≤ –15%) with a distinctive “apical-sparing” pattern—meaning the tip of the heart retains some motion while the base and mid-chamber are markedly stiffened. This pattern is visible in over 85% of ATTR cases and helps distinguish infiltration from pressure overload.

• Biomarker discordance is telling. Troponin I or T may be normal or only minimally elevated in early cardiac amyloidosis—even as NT-proBNP rises disproportionately (often >1,500 pg/mL despite preserved ejection fraction). In contrast, hypertensive heart disease tends to show more balanced biomarker elevation. A ratio of NT-proBNP >1,000 pg/mL with troponin <0.03 ng/mL is a recognized red flag for amyloidosis in older adults.

• Bone scintigraphy (e.g., technetium-99m pyrophosphate scan) is highly specific for ATTR amyloidosis when combined with absent monoclonal protein on blood/urine testing. It’s non-invasive, widely available, and avoids the need for biopsy in most cases—a reassuring advancement for older patients.

Who should pay special attention? Adults aged 77+ with:

• LVH on echo but systolic BP consistently <140 mm Hg (or well-controlled on ≤2 medications),
• Unexplained carpal tunnel syndrome or lumbar spinal stenosis (both occur in ~25–30% of ATTR patients, often years before cardiac symptoms),
• A family history of heart failure or unexplained sudden death,
• Or progressive diastolic dysfunction (e.g., E/e′ ratio >15) without clear hypertension or diabetes.

Practical Steps You Can Take—Gently and Wisely

You don’t need to diagnose yourself—and you shouldn’t try. But you can partner meaningfully with your care team by staying informed and observant.

Start with awareness: Notice subtle shifts—not just chest pain, but things like needing two pillows to sleep comfortably, feeling winded walking across a room, or swelling in the ankles that doesn’t fully improve overnight. These aren’t “just aging.” They’re signals worth sharing.

Lifestyle support remains foundational—for both conditions. Prioritize heart-healthy habits that ease strain on the heart muscle:

• Choose whole foods rich in potassium and magnesium (leafy greens, bananas, avocados, unsalted nuts) to support healthy vascular tone.
• Stay gently active—aim for 20–30 minutes of walking most days; even seated leg lifts or arm circles improve circulation.
• Limit added salt to under 1,500 mg daily—especially helpful if diastolic stiffness is present.
• Prioritize restful sleep; untreated sleep apnea can worsen both hypertensive remodeling and amyloid deposition.

Self-monitoring helps ground conversations with your doctor. Keep track of:

• Daily blood pressure readings (morning and evening, same arm, seated and rested for 5 minutes),
• Weight trends (a sudden gain of ≥4 pounds in 3 days may signal fluid retention),
• Symptom notes—what triggered shortness of breath? How long did swelling last?

Tracking your blood pressure trends can help you and your doctor make better decisions. Consider keeping a daily log or using a monitoring tool to stay informed.

See your doctor sooner—not later—if you notice:

• Increasing fatigue that doesn’t lift with rest,
• Lightheadedness or near-fainting with standing,
• New or worsening swelling in feet, legs, or belly,
• Or if your usual medications seem less effective or cause new side effects (e.g., dizziness with BP meds).

A Reassuring Perspective

It’s completely understandable to feel uncertain when heart changes appear—but uncertainty doesn’t mean helplessness. Today’s cardiology offers clearer, kinder, and more precise ways to understand what’s happening inside your heart. Whether the cause is long-standing arterial pressure or an infiltrative process like cardiac amyloidosis vs hypertensive heart disease, knowing the “why” opens the door to personalized care, earlier support, and greater confidence in your health journey. If you're unsure, talking to your doctor is always a good idea.

FAQ

#### What are the key differences between cardiac amyloidosis vs hypertensive heart disease?

Cardiac amyloidosis involves abnormal protein deposits that stiffen the heart muscle, often without high blood pressure, while hypertensive heart disease results from years of elevated arterial pressure causing adaptive thickening. Amyloidosis commonly shows disproportionate NT-proBNP elevation, apical-sparing strain on echo, and may present with carpal tunnel or spinal stenosis—features rarely seen in pure hypertensive remodeling.

#### Can cardiac amyloidosis vs hypertensive heart disease be mistaken for each other in older adults?

Yes—especially in adults 77+, where both conditions share overlapping features like LVH and diastolic dysfunction. Up to 20% of older adults initially diagnosed with hypertensive heart disease are later reclassified after advanced testing reveals amyloidosis. That’s why “unexplained LVH” warrants thoughtful follow-up—not assumptions.

#### Does normal troponin rule out cardiac amyloidosis?

No. In early or wild-type transthyretin (ATTRwt) cardiac amyloidosis, troponin levels often remain within the normal range—even as the heart sustains microscopic injury. Relying solely on troponin can delay diagnosis; combining it with NT-proBNP, strain imaging, and clinical clues provides much more reliable insight.

#### Why does obesity make ECG interpretation less reliable in diagnosing LVH?

Excess body fat dampens electrical signals traveling from the heart to skin electrodes, reducing QRS voltage amplitude. As a result, up to 40% of obese older adults with confirmed LVH on echocardiography will have a “normal-voltage” ECG—making echo and strain imaging far more dependable for detecting true structural change.

#### Is cardiac amyloidosis treatable in older adults?

Yes—and increasingly so. For wild-type ATTR amyloidosis (the most common type in adults over 75), medications like tafamidis stabilize the transthyretin protein and slow progression. Supportive care—including careful BP management and symptom relief—is highly effective. Early recognition leads to better outcomes and improved quality of life.